About this document
Neoadjuvant Pembrolizumab Plus Chemotherapy by Giancarlo Maruri Munaretto is a document available to read on EtoBox.
The KEYNOTE-671 trial demonstrated that adding neoadjuvant pembrolizumab to chemotherapy significantly improves overall survival and event-free survival in patients with early-stage non-small-cell lung cancer (NSCLC) compared to chemotherapy alone. The study involved 797 participants and showed a 36-month overall survival estimate of 71% in the pembrolizumab group versus 64% in the placebo group. The findings support the use of perioperative pembrolizumab as a standard treatment option for patients with res
- Author
- Giancarlo Maruri Munaretto
- Language
- EN